Gelox

shielding antacid containing montmorillonite beidellite, aluminum hydroxide & magnesium hydroxide

Networked: 5 relevant articles (2 outcomes, 1 trials/studies)

1.	Lymphoma (Lymphomas) 01/01/2015 - "A total of fifty-one cases with nasal natural killer/T-cell lymphoma receiving initial GELOX chemotherapy were enrolled in this study. " 03/01/2014 - "Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up." 01/01/2015 - "Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma." 01/15/2013 - "First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma."
2.	Extranodal NK-T-Cell Lymphoma 09/01/2015 - "Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma."
3.	T-Cell Lymphoma (Lymphoma, T Cell) 06/16/2022 - "Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime."